Scholars Central

Conference abstractPublished 2018

Possible protective effect of Procainamide as an epigenetic modifying agent in experimentally induced type-2 diabetes mellitus in rats

Authors: Wessam Fahmy El-Hadidy

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Diabetes mellitus occurs due to insulin deficiency and/or impaired insulin action. Epigenetic mechanisms were shown to be involved in endocrine cell differentiation and islets function. Procainamide an antiarrhythmic drug has been recently classified as an epigenetic drug targeting DNA methylation. The present study was designed to evaluate the effect of procainamide as a demethylating agent on streptozotocin-induced type-2 DM in rats. Fifty (50) adult male albino rats were divided into five groups: Group-1: Normal control, Group-2: Diabetic untreated, Group-3: Procainamide-treated diabetics, Group-4: Metformin-treated diabetics and Group-5: Combined procainamide and metformin-treated diabetics for 4 weeks. Fasting blood glucose level, serum insulin and Tumor Necrosis Factor alpha (TNF-?) levels and DNA Methyltransferase Enzyme (DNMT) activity in pancreatic tissues were assessed. Results revealed that combined administration of procainamide and metformin produced a statistically significant reduction of fasting blood glucose levels as compared to untreated diabetic rats and diabetic treated by either procainamide or metformin alone. Procainamide resulted in a statistically significant rise of serum insulin levels. TNF-? levels were statistically elevated in diabetic untreated rats and those treated with metformin only while procainamide led to its statistical decrease. Also, procainamide produced a statistically significant reduction in the activity of DNMT in pancreatic tissues. Thus our work could provide a proof of concept that procainamide could be used as a possible therapeutic potential in type-2 diabetics as an epigenetic demethylating agent to increase insulin levels and it is better to be used in combination with oral hypoglycemic agent to decrease insulin resistance.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Diabetes & Metabolism.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Diabetes & Metabolism
  • SubjectDiabetes & Endocrinology
  • BylineArticles whose byline prints “Wessam Fahmy El-Hadidy”